Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine on a molar basis in inhibiting stimulated gastric acid secretion. Clinical studies have demonstrated that ranitidine is as effective as cimetidine and is similarly well tolerated.
Based on available literature (approximately 700 publications), this article reviews the pharmacology, safety profile, and clinical efficacy of ranitidine in duodenal ulcers and gastric hypersecretory conditions.
BlackJWDuncanWAMDurantCJGanellinCRParsonsME. Definition and antagonism of histamine H2-receptors. Nature1972; 236: 385–90.
2.
CodeCF. Histamine and gastric secretion: a later look, 1955–1965. Fed Proc1965; 24: 1311–21.
3.
CodeCF. Reflections on histamine, gastric secretion and the H2-receptor. N Engl J Med1977; 294: 1459–62.
4.
BrogdenRNCarmineAAHellRCSpeightTMAveryGS. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs1982; 24: 267–303.
5.
KonturekSJ. Pharmacology and clinical use of ranitidine. Mt Sinai J Med1982; 49: 370–82.
6.
BrittainRTDalyMJ. A review of the animal pharmacology of ranitidine—a new, selective histamine H2-antagonist. Scand J Gastroenterol1981; 16 (suppl 69): 1–8.
7.
DalyMJHumphrayJMStablesR. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol1981; 72: 49–54.
8.
BrittainRTDalyMJJackDMartinLEStablesRSutherlandM. The outline of the animal pharmacology of ranitidine. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 1–10.
9.
DalyMJHumphrayJMStablesR. Antagonism of vasodepressor and gastric secretory responses to histamine by the H2-receptor antagonists ranitidine and cimetidine, in the anesthetized dog. Br J Pharmacol1981; 72: 55–60.
10.
DalyMJHumphrayJMStablesR. Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine and metiamide. Gut1980; 21: 408–12.
11.
CheretAMPignalFLewinMJM. Effects of H2-receptor antagonists cimetidine, ranitidine and ICI 125,211 on histamine-stimulated adenylate cyclase activity in guinea pig gastric mucosa. Mol Pharmacol1981; 20: 326–30.
12.
AingeGPoynterD. H2-receptor antagonists: ultrastructure of canine parietal cells after long term treatment with ranitidine. Scand J Gastroenterol1981; 16 (suppl 70): 143–54.
13.
KonturekSJCieszkowskiMKwiecienNHarrisonC. Gastric acid response to topical or intravenous histamine and topical H2-receptor blockade in dogs. Agents Actions1981; 11: 437–41.
14.
KonturekSJRadeckiTBrzozowskiTPiastuckiIDembinska-KiecAZmudaA. Gastric cytoprotection by prostaglandins, ranitidine and probanthine in rats. Role of endogenous prostaglandins. Scand J Gastroenterol1981; 16: 7–12.
15.
BunceKTDalyMJHumphrayJMStablesR. H2-receptor antagonists protect against aspirin-induced gastric lesions in the rat. Agents Actions1981; 11: 167–70.
16.
MartinACovazLSturnioloGCNaccaratoR. Effect of H2-antagonists and carbenoxolone on prostaglandin E (PGE) synthesis in the rat stomach. Ital J Gastroenterol1981; 13: 273.
17.
KonturekSJObtulowiczWKwiecienNSitoEMikosEOleksyJ. Comparison of ranitidine and cimetidine in the inhibition of histamine, sham-feeding and meal-induced gastric secretion in duodenal ulcer patients. Gut1980; 21: 181–6.
18.
KonturekSJObtulowiczWKwiecienNSitoEOleksyJMiszcuk-JamskaB. Effect of ranitidine, a new H2-antagonist on gastric and pancreatic secretion in duodenal patients. Dig Dis Sci1980; 25: 737–43.
19.
SewingK-FRBillianAMalchowH. Comparative study with ranitidine and cimetidine on gastric secretion in normal volunteers. Gut1980; 21: 750–2.
20.
BraterDCPetersMNEshelmanFNRichardsonCT. Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther1982; 32: 484–9.
21.
WaltRPPriceDKRawlingsJHuntRHMilton-ThompsonGJMisiewiczJJ. Is ranitidine longer-acting than cimetidine?. Gut1980; 21: A898.
22.
WaltRPMalePJRawlingsJHuntRHMilton-ThompsonGJMisiewiczJJ. Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer. Gut1981; 22: 49–54.
23.
DammannHGSimonB. The new histamine H2-receptor antagonist ranitidine—duration of action. Scand J Gastroenterol1981; 16 (suppl 69): 39–43.
24.
GalmicheJPDesechalliersJPDenisPChevallierBColinR. Ranitidine treatment of cimetidine-resistant peptic ulcers: preliminary clinical and 24-hour intragastric acidity results. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Series 5. Oxford: Medicine Publishing Foundation, 1982: 243–50.
25.
HansonRGMihalyGWSmallwoodRALouisWJYeomansNO. The inhibition of gastric acid secretion by ranitidine: the effects of 6 weeks ranitidine therapy. Gastroenterology1981; 80: 1168.
26.
MohammedRHoldenRJHearnsJBMcKibbenBMBuchananKDCreanGP. Effect of eight weeks continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion and fasting serum gastrin. Gut1983; 24: 61–6.
27.
SheersRRobertsN. The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion. Scand J Gastroenterol1981; 16: 51–7.
EckhartVFCordesIJanischHDWiemanH. Daytime acid secretion after a single dose of ranitidine and cimetidine—a double blind crossover study. Gastroenterology1983; 84: 1144.
30.
PedenNRSaundersJHBWormsleyKG. Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. Lancet1979; 1: 690–2.
31.
DomschkeWLuxGDomschkeS. Gastric inhibitory action of H2-antagonists ranitidine and cimetidine. Lancet1979; 1: 320.
32.
GuslandiMBallarinETittobelloA. Gastric mucus secretion in ranitidine-treated patients. Br Med J1981; 2: 699.
33.
GabryelewiczASarosiekJLaszewiczW. The effect of ranitidine on gastric mucus, pepsin and hydrochloric acid secretion in patients with duodenal ulcer. Acta Medica Polana1981; 22: 335–9.
34.
WallinLMadsenTBoesbyS. Gastro-oesophageal function in normal subjects after oral administration of ranitidine. Gut1983; 24: 154–7.
35.
ThomasJMTrotmanIFMisiewiczJJ. Ranitidine and lower oesophageal sphincter pressure. Lancet1983; 1: 418.
MarlettaFMonelloSSalaLOBrognaAScolloLBlasiA. Effects of ranitidine on lower esophageal sphincter pressure in normal subjects and in patients with gastro-oesophageal reflux. Ital J Gastroenterol1981; 13: 276.
38.
BertacciniGScarpignatoC. Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol1982; 77: 443–8.
39.
ScarpignatoCBertacciniGZimbaroGVituloF. Ranitidine delays gastric emptying of solids in man. Br J Clin Pharmacol1982; 13: 252–3.
40.
MignonMChauNPNguyen-PhuocBKSauvageMLeguyFBonfilsS. Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. Br J Clin Pharmacol1982; 14: 187–93.
41.
PearcePFunderJW. Histamine H2-receptor antagonist: radioreceptor assay for antiandrogenic side effects. Clin Exp Pharmacol Physiol1980; 7: 442.
42.
PedenNRBoydEJSBrowningMCKSaundersJHBWormsleyKG. Effects of two histamine H2-receptor blocking drugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17-beta during treatment of duodenal ulcer in male patients. Acta Endocrinologica1981; 96: 564–8.
43.
BohnetHGRileyAJ. An investigation of the effect of oral ranitidine treatment on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal function in male and female volunteers. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 78–81.
44.
KniggeUDejgaardAWollesenFIngersleuOBennettPChristiansenPM. The acute and long term effect of the H2-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in men. Clin Endocrinol1983; 18: 307–13.
45.
WaltRPLaBrooySJAvgerinosAOehrTRileyAMisiewiczJJ. Investigation on the penetration of ranitidine into the cerebrospinal fluid and a comparison of the effects of ranitidine and cimetidine on male sex hormones. Scand J Gastroenterol1981; 16 (suppl 69): 19–25.
46.
EdwardsCRWRileyAJ. Endocrine effects of ranitidine: comparison with cimetidine. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 65–9.
47.
SanniaABennaGM. LH, FSH, and PRL levels after a high intravenous dose of ranitidine. IRCS Med Sci1982; 10: 126.
48.
NelisGFVan de MeeneJGC. Comparative effect of cimetidine and ranitidine on prolactin secretion. Postgrad Med J1980; 56: 478–80.
49.
RobinsAHMcFaydenML. Effect of the new H2-receptor antagonist ranitidine on plasma prolactin levels in duodenal ulcer patients. J Pharm Pharmacol1981; 33: 590–3.
50.
CavalliniGVaonaBAngeliniG. Gastric, pancreatic exocrine and endocrine functional aspects of short-term treatment with ranitidine. Ital J Gastroenterol1981; 13: 289–90.
51.
YeoTDelitaliaGBesserGMEdwardsCRW. The effects of ranitidine on pituitary hormone secretion in vitro. Br J Clin Pharmacol1980; 10: 171–3.
52.
CorinaldesiRPasqualiRCapelliM. Effect of acute oral and intravenous administration of ranitidine on prolactin, thyrotropin and gonadotropin serum levels. Hepato-gastroenterol1982; 29: 120–3.
53.
FrancavillaAPanellaCIerardiE. Effects of cimetidine and ranitidine intravenous administration on serum prolactin levels in man. Ital J Gastroenterol1981; 13: 289.
54.
KniggeUWollesenFDejgaardAThuesenBChristiansenPM. Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H2-receptor antagonists in normal men. Clin Endocrinol1981; 15: 585–92.
55.
EdwardsCRWYeoTDelitaliaG. In vitro studies on the effects of ranitidine on isolated anterior pituitary and adrenal cells. Scand J Gastroenterol1981; 16 (suppl 69): 75–9.
56.
RileyAJMaconochieJ. Effect of histamine H2-receptor antagonists on vasopressin and basal aldosterone secretion in man. Acta Endocrinol1981; 97 (suppl 243): A316.
57.
PasqualiRCorinaldesiRMiglioliM. Effect of prolonged administration of ranitidine on pituitary and thyroid hormones, and their response to specific hypothalamic-releasing factors. Clin Endocrinol1981; 15: 457–62.
58.
TarditiEValentiGScarpignatoCBertacciniG. Impaired TSH response to TRH after intravenous ranitidine in man. Experientia1983; 39: 109–10.
59.
CorinaldesiRPasqualiRTononR. Effect of chronic administration of ranitidine on the response of gonadotrophins, prolactin and TSH to releasing hormones and on the basal concentrations of thyroid and sexual hormones. Ital J Gastroenterol1981; 13: 61–2.
60.
BarbatJWarringtonSJ. Effects of cimetidine and ranitidine on some non-invasive indices of cardiac function. Br J Pharmacol1981; 72: 131.
61.
LiedbergGFletcherEDaviesJ. Cimetidine, ranitidine and heart rate. Lancet1982; 2: 265.
62.
JacksonGUpwardJW. Cimetidine, ranitidine and heart rate. Lancet1982; 2: 265.
63.
JackDRichardsDAGranataF. Side-effects of ranitidine. Lancet1982; 2: 264–5.
64.
PuppoFCorsiniGManginiP. Ranitidine does not modify lymphocyte in vitro reactivity to the mitogens PHA, Con A and PWM. IRCS Med Sci1982; 10: 538.
65.
BovoPVaonaBAngeliniG. Ranitidine and delayed hypersensitivity. Ital J Gastroenterol1981; 13: 49.
66.
PedenNRRobertsonAJBoydEJS. Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine. Gut1982; 23: 398–403.
67.
MinariniAPiazzaGCChilliL. Action of ranitidine on some functions of the immunological system (IS): a preliminary report. Ital J Gastroenterol1981; 13: 289.
68.
JansenECBrynskovJThyssenHH. Influence of ranitidine on postural stability. Lancet1982; 1: 55–6.
69.
SzabadiETheofilopuolosNBradshawCM. Effect of ranitidine on psychomotor functions: comparison with cimetidine and thioridazine. Br J Clin Pharmacol1983; 15: 153.
70.
PedrazzoliSPetrinPPasqualiC. Ranitidine reverses cimetidine-induced mental confusion in a patient with Zollinger-Ellison syndrome. Arch Surg1983; 118: 256.
71.
BoriesPMichellHDuclosBBeraudJJMirouzeJ. Use of ranitidine, without mental confusion in patient with renal failure. Lancet1980; 2: 755.
72.
MohammedRClarkJSAdamsJFHearnsJBCreanGP. The effect of ranitidine hydrochloride, a new histamine H2-receptor antagonist on intrinsic factor secretion, Clin Ther1981; 4: 118–20.
73.
YeomansNDHansonRGSmallwoodRAMihalyGWLouisWJ. Effect of chronic ranitidine treatment on secretion of intrinsic factor. Br Med J1982; 2: 264.
74.
BelaicheJZeittounJ. Effect of chronic ranitidine treatment on secretion of intrinsic factor. Br Med J1982; 2: 890–1.
75.
LubckePHerrmannW. Effects of cimetidine and ranitidine on plasmatic blood coagulation. Deutsch Med Woch1982; 107: 1671–4.
76.
WangCLaiCLLamKCWongKL. Ranitidine does not affect gonadal function in man. Scand J Gastroenterol1982; 17 (suppl 78): A947.
77.
HagenmullerFUsadelKHSchwedesUZeitlerAClassenM. Ranitidine and cimetidine: investigation of the inhibition of gastric acid secretion and of antiandrogenic properties. Innere Medizin1982; 9: 347–52.
78.
MartinLEOxfordJTannerRJN. The use of on-line high-performance liquid chromatography-mass spectrometry for the identification of ranitidine and its metabolites in urine. Xenobiotica1981; 11: 831–40.
79.
CareyPFMartinLE. A high performance liquid chromatography method for the determination of ranitidine in plasma. J Liquid Chromatogr1979; 2: 1291–303.
80.
CareyPFMartinLEOwenPA. A method for the determination of ranitidine and its metabolites in urine by HPLC and its application to study the metabolism and pharmacokinetics of ranitidine in man. Biochem Soc Trans1981; 9: 112.
81.
BellJABradburyAMartinLETannerRJN. Applications of high voltage paper electrophoresis for the characterization of drug metabolites. Xenobiotica1981; 11: 841–7.
82.
JennerWMartinLEWilloughbyBAFellowsI. The development of a radioimmunoassay for ranitidine in biological fluids. Life Sci1981; 28: 1323–9.
83.
FellowsIJennerWNMartinLEWilloughbyBA. The development of a radioimmunoassay for ranitidine in biological fluids. Br J Pharmacol1981; 73: 274–5.
84.
LouisWJMihalyGWHansonRG. Pharmacokinetic and gastric secretory studies of ranitidine in man. Scand J Gastroenterol1981; 16 (suppl 69): 11–17.
85.
BoguesKDixonGTFowlerP. Pharmacokinetics and bioavailability of ranitidine in humans. Br J Pharmacol1981; 73: 275–6.
86.
Van HeckenAMTjandramagaTBMullieAVerbesseltRDeSchepperPJ. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol1982; 14: 195–200.
87.
WoodingsEPDixonGTHarrisonCCareyPRichardsDA. Ranitidine—a new H2-receptor antagonist. Gut1980; 21: 187–91.
88.
ChauNPZechPYPozetNHadj-AissaA. Ranitidine kinetics in normal subjects. Clin Pharmacol Ther1982; 31: 770–4.
89.
BerstadAFrislidKRydningA. Relationship between ranitidine plasma levels and reduction of postprandial intragastric acidity in healthy man. Scand J Gastroenterol1982; 17: 109–12.
90.
SewingK-FR. Pharmacodynamics and pharmacokinetics of ranitidine in man. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 32–40.
91.
MihalyGWMarinoATWebsterLKJonesDBLouisWJSmallwoodRA. High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J1982; 2: 998–9.
92.
EshelmanFNPlachetkaJRBrownDCP. Effect of antacid and anticholinergic medication on ranitidine absorption. Clin Pharmacol Ther1983; 33: 216.
93.
FrislidKBerstadA. High dose of antacid reduces bioavailability of ranitidine. Br Med J1983; 1: 1358.
94.
LittmanAPineBH. Antacids and anticholinergic drugs. Ann Intern Med1975; 82: 544–57.
95.
PiperDW. Antacid and anticholinergic drug therapy of peptic ulcer. Gastroenterology1967; 52: 1009–18.
96.
McGonigleRJSWilliamsLCAmphlettGEEnglandRJParsonsV. The pharmacokinetics of ranitidine in renal disease. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 41–7.
97.
LebertPAMacLeodSMMahonWASoldinSJVandenbergheHM. Ranitidine kinetics and dynamics. Clin Pharmacol Ther1981; 30: 539–44.
98.
GargDCWeidlerDJEshelmanFN. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther1983; 33: 452.
99.
McNeilJJMihalyGWAndersonAMarshallAWSmallwoodRALouisWJ. Pharmacokinetics of the H2-receptor antagonist ranitidine in man. Br J Clin Pharmacol1981; 12: 411–5.
100.
MihalyGWMorganDJMarshallAW. Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. J Pharm Sci1982; 71: 1008–10.
101.
RileyAJCrowleyPHarrisonC. Transfer of ranitidine to biological fluids: milk and semen. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 78–81.
102.
BellJADallasFAAJennerWNMartinLE. The metabolism of ranitidine in animals and man. Biochem Soc Trans1980; 9: 93.
103.
BrittainRT. Discovery and evolution of ranitidine. In: RileyAJSalmonPR, eds. Ranitidine, proceedings of an international symposium held in the context of the Seventh World Congress of Gastroenterology. Amsterdam: Excerpta Medica, 1982: 5–14.
104.
Package insert. Zantac. Glaxo, Inc., Ft. Lauderdale, FL, May 1983.
105.
McGonigleRJSWilliamsLCAmphlettGEEnglandRJParsonsV. Ranitidine clearance in patients with renal impairment. Scand J Gastroenterol1982; 17 (suppl 78): A435.
106.
YoungCJDaneshmendTKRobertsCJC. Effect of cirrhosis and ageing on the elimination and bioavailability of ranitidine. Gut1982; 23: 819–23.
107.
Colin-JonesDG. Ranitidine in the treatment of peptic ulceration. In: RileyAJSalmonPR, eds. Ranitidine, proceedings of an international symposium held in the context of the Seventh World Congress of Gastroenterology. Amsterdam: Excerpta Medica, 1982: 16–29.
108.
PedenNRBoydEJSSaundersJHBWormsleyKG. Ranitidine in the treatment of duodenal ulceration. Scand J Gastroenterol1981; 16: 325–9.
109.
ZeittounPD'AzemarP. International multicentre clinical trial of ranitidine in duodenal ulcer. Comparison with cimetidine. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 143–7.
110.
MarksINWrightJPDenyerMHatfieldAGirdwoodAHLuckeW. Ranitidine heals duodenal ulcers. S Afr Med J1982; 61: 152–4.
111.
MoshalMGSpitaelsJMKhanF. A double-blind endoscopically controlled trial of ranitidine in a high incidence area. Scand J Gastroenterol1981; 16 (suppl 69): 129–31.
112.
LeeFIFieldingJDMacKayC. Comparison of twice daily ranitidine and placebo in the treatment of duodenal ulcer—a multicenter study in the United Kingdom. Hepato-gastroenterology1982; 29: 127–9.
113.
PorroG BianchiPetrilloMLazzaroniM. Ranitidine in the short term treatment of duodenal ulcer: a multicentre endoscopic double-blind trial. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 136–42.
114.
GibinskiKNowakAGabryelewiczA. Treatment of duodenal ulcer and gastric ulcer with ranitidine: a controlled multicentre clinical trial. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 172–7.
115.
van DommelenCKVStadlerFHBoekhorstJC. Comparison of ranitidine with cimetidine in the treatment of duodenal ulcer. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 154–6.
116.
LishmanAHRecordCO. The use of ranitidine in the management of duodenal ulcer: controlled and open comparison with cimetidine in 59 patients. J Clin Gastroenterol1982; 4: 421–4.
117.
LeeFIFieldingJDCostelloFT. Ranitidine compared with cimetidine in the short-term healing of duodenal ulcer. Postgrad Med J1983; 59: 88–92.
118.
WaltRPTrotmanIFFrostR. Comparison of twice daily ranitidine with standard cimetidine treatment of duodenal ulcer. Gut1981; 22: 319–22.
119.
BarrGDParisCHMiddletonWRJPiperDW. Comparison of ranitidine and cimetidine in duodenal ulcer healing. Med J Aust1982; 2: 83–5.
120.
TakemotoTOkitaKNamikiMIshikawaMOshibaS. Clinical studies on gastric ulcer in Japan—pilot and extended open studies. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Seris 5. Oxford: Medicine Publishing Foundation, 1982: 222–31.
121.
JensenRTCollenMJPandelSJ. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med1983; 308: 883–7.
122.
StabileBEIppolitiAFWalshJHPassaroE. Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome. Am J Surg1983; 145: 17–23.
123.
BonfilsSMignonMVallotTHMayeurS. Use of ranitidine in the medical treatment of Zellinger-Ellison syndrome. Scand J Gastroenterol1981; 16 (suppl 69): 119–23.
124.
PazzagliaMVezzadiniPTomassettiP. Ranitidine in the treatment of Zollinger-Ellison syndrome. Scand J Gastroenterol1982; 17 (suppl 78): A1007.
125.
PedrazzoliSPasqualiCZanniniGFregoneseVBertelaGPetrinP. Use of cimetidine and ranitidine in the medical treatment of Zollinger-Ellison syndrome. Scand J Gastroenterol1982; 17 (suppl 78): A1009.
126.
MignonMVallotTMayeurSAguerroGMeroucheMBonfilsS. Respective influence on 24-hour gastric acidity of cimetidine and ranitidine in 6 cases of Zollinger-Ellison syndrome (ZES). Gastroenterology1981; 80: 1232.
127.
CollenMJHowardJMMcArthurKERaufmanJPGardnerJDJensenRT. Long-term medical therapy with ranitidine in patients with Zollinger-Ellison syndrome (ZES). Gastroenterology1983; 84: 1127.
128.
MohammedRMitchellKGMacKayC. The treatment of ‘cimetidine resistant’ peptic ulcers by ranitidine hydrochloride: a new histamine H2-receptor antagonist. Curr Med Res Opin1981; 7: 523–5.
129.
BrunnerGLesgenHHarkeU. Ranitidine in the treatment of cimetidine-resistant ulcerations of the upper intestinal tract. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 254–6.
130.
WitzelLWolbergsE. Peptic ulcer healing with ranitidine and cimetidine resistance. Lancet1982; 2: 1224.
131.
DanilewitzMTimL OuHirschowitzB. Ranitidine suppression of gastric hypersecretion resistant to cimetidine. N Engl J Med1982; 306: 20–2.
132.
MazzaccaGD'AgostinoLD'ArienzoAPiaiGSabbatiniFVerreC. Cimetidine or ranitidine nen-responder patients. Treatment of duodenal ulcers resistant to one H2-blocker with the other. Scand J Gastroenterol1982; 17 (suppl 78): A408.
133.
SimonBMullerPDammannHG. Safety profile of ranitidine. In: RileyAJSalmonPR, eds. Ranitidine, proceedings of an international symposium held in the context of the Seventh World Congress of Gastroenterology. Amsterdam: Excerpta Medica, 1982: 181–9.
134.
KormanMGHanskyJMerretACSchmidtGT. Ranitidine in duodenal ulcer. Incidence of healing and effect of smoking. Dig Dis Sci1982; 27: 712–5.
135.
JonesDBRoseJDRSmithPMCalcraftBJ. Treatment of peptic ulcer with ranitidine—a clinical trial. In: MisiewiczJJWormsleyKG, eds. The clinical uses of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 185–8.
136.
DumontA BarbierAdlerM. The treatment with ranitidine of 40 gastro-duodenal ulcerations: evaluation of an open study. Acta Gastroenterol Belg1979; 42: 268–74.
137.
BarrGDPiperDW. Possible ranitidine hepatitis. Med J Aust1981; 2: 241.
138.
TosiRCagnoliM. Painful gynecomastia with ranitidine. Lancet1982; 2: 160.
139.
Package insert. Tagamet. Smith Kline & French, Philadelphia, PA, Jan 1983.
140.
LombardoL. Reversible amenorrhoea after ranitidine treatment. Lancet1982; 1: 224.
ShahRR. Symptomatic bradycardia in association with H2-receptor antagonists. Lancet1982; 2: 1108.
143.
DobrillaGFelderMChiloviFde PretisG. Exacerbation of glaucoma associated with both cimetidine and ranitidine. Lancet1982; 1: 1078.
144.
FeldmanFCohenMM. Intraocular pressure and H2-receptor antagonists. Lancet1982; 1: 1359.
145.
PotterPHWestbyRG. Interstitial nephritis after cimetidine but not ranitidine. JAMA1983; 249: 351.
146.
DeFloraSBennicelliCCamoiranoAZanacchiP. Genotoxicity of nitrosated ranitidine. Carcinogenesis1983; 4: 255–60.
147.
BrittainRTHarrisDMMartinLEPoynterDPriceBJ. Safety of ranitidine. Lancet1981; 2: 1119.
148.
SomogyiAGuglerR. Drug interactions with cimetidine. Clin Pharmacokinet1982; 7: 23–41.
149.
BaumanJHKimelblattBJ. Cimetidine as an inhibitor of drug metabolism: therapeutic implications and review of the literature. Drug Intell Clin Pharm1982; 16: 380–6.
150.
SilverBABellWR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med1979; 30: 348–9.
151.
LofgrenRPGilbertsonRA. Cimetidine and theophylline. Ann Intern Med1982; 96: 378.
152.
WattsRWHetzelDJBochnerFHallpikeJFHannCSShearmanDJC. Lack of interaction between ranitidine and Phenytoin. Br J Clin Pharmacol1983; 15: 499–500.
153.
FeeleyJWilkinsonGRMcAllisterCB. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med1982; 96: 592–4.
154.
SpeegKVPatwardhanRVAvantGRMitchellMCSchekerS. Inihibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology1982; 82: 89–96.
155.
KnodenRGHoltzmanJLCrankshawDLSteeleNNStanleyLN. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology1982; 82: 84–8.
156.
BellJAGowerAJMartinLEMillsENSmithWP. Interaction of H2-receptor antagonists with drug metabolizing enzymes. Biochem Soc Trans1981; 9: 113–4.
157.
RendicSKajfezFRufHH. Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450. Drug Metab Dispos1983; 11: 137–42.
158.
RendicSAlebic-KolbahTKajfezF. Interaction of ranitidine with liver microsomes. Xenobiotica1982; 12: 9–17.
159.
StaigerCSimonBWalterEKatherH. Influence of ranitidine on antipyrine pharmacokinetics in healthy volunteers. Dig Dis Sci1981; 25: 894.
160.
HenryDAMacDonaldIAKitchingmanGBellGDLangmanMJS. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J1980; 2: 775–7.
161.
SerlinM JSibeonRGBreckenridgeAM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol1981; 12: 791–4.
162.
O'ReillyRA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Fed Proc1983; 42: 1175.
163.
PowellJRRogersJFWarginWACrossREEshelmanFN. The influence of cimetidine vs. ranitidine on theophylline pharmacokinetics. Clin Pharmacol Ther1982; 31: 261.
164.
BreenKJBuryRDesmondPV. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin Pharmacol Ther1982; 31: 297–300.
165.
RuffF. Drug interactions with theophylline. Lack of theophylline-ranitidine interaction. Nouv Presse Med1982; 11: 3512.
166.
KlotzUReimannIWOhnhausEE. Effect of ranitidine on the steady state pharmacokinetics of diazepam. Eur J Clin Pharmacol1983; 24: 357–60.
167.
AbernathyDRGreenblattDJEshelmanFNShaderRI. Ranitidine noninteraction with benzodiazepine oxidation or conjugation. Clin Pharmacol Ther1983; 33: 216.
168.
FeelyJGuyE. Lack of effect of ranitidine on the disposition of lignocaine. Br J Clin Pharmacol1983; 15: 378–9.
169.
JacksonJEBentleyJBGlassSBannerWPlachetkaJD. The effects of H2-blockers on lidocaine disposition. Clin Pharmacol Ther1983; 33: 255.
170.
ReimannIWKlotzUFrolichJC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther1982; 32: 749–58.
171.
HeagertyAMCastledenCMPatelL. Failure of ranitidine to interact with propranolol. Br Med J1982; 1: 1304.
172.
PatelLWeerasuriyaK. Effect of cimetidine and ranitidine on propranolol clearance. Br J Clin Pharmacol1983; 15: 152.
173.
JanischHDSpahnHKirchWOhnhausEEMutschierE. Interaction between ranitidine and betareceptor blockers like metoprolol and atenolol. Gastroenterology1983; 84: 1197.
174.
SeitzHKBoscheJCzyganPVeithSSimonBKommerellB. Increased blood ethanol levels following cimetidine but not ranitidine. Lancet1983; 1: 760.
175.
MavierPPreauxAMDelchierJCBeauchantMDhumeauxD. Comparative effects of cimetidine and ranitidine on liver microsomal drug-metabolizing enzyme system studied in vivo and in vitro in the rat. Gastroenterol Clin Biol1983; 7: 244–50.
176.
MitchellMCSchenkerSSpeegKV. Differential effects of cimetidine (C) and other H2-receptor antagonists on acetaminophen metabolism. Clin Res1981; 29: 758A.
177.
LeeHRGandolfiAJSipesIGBethlyJ. Effect of histamine H2-antagonists on fentanyl metabolism. Pharmacologist1982; 24: 145.
178.
DesmondPVBreenKJHarmanPJMashfordMLMorphettBJ. Decreased clearance of warfarin after treatment with cimetidine or ranitidine. Gastroenterological Society of Australia, Scientific Meeting, Oct 11–12, 1982, Melbourne.
179.
ElwoodRJHildebrankPJDundeeJWCollierPS. Influence of ranitidine on uptake of oral midazolam. Br J Anaesth1983; 55: 241.
180.
FeelyJGuyE. Ranitidine also reduces liver blood flow. Lancet1982; 1: 169.
181.
GargDCWeidlerDJJalladNSEshelmanFN. The effects of ranitidine and cimetidine on hepatic blood flow. Clin Pharmacol Ther1982; 31: 228–9.
182.
KlotzUReimannIW. Drug interactions with H2-receptor blocking agents. In: TytgatGN, ed. Ranitidine, the selective new H2-receptor antagonist. Proceedings of a symposium held in Amsterdam, Sept 17–18, 1982. Guildford: Baskerville Publishers Ltd., 1982: 46–53.
183.
DesmondPVBreenKJHarmanP. No effect of ranitidine on the disposition or elimination of chlormethiazole or indocyanine green (ICG). Scand J Gastroenterol1982; 17 (suppl 78): A50.
184.
SochaJRondioHChaba-CelinskaDRasinskiABogoniowskaZ. Ranitidine treatment of peptic and related diseases in children. In: MisiewiczJJWormsleyKG, eds. The clinical use of ranitidine. Medicine Publishing Foundation Symposium Series 5. Oxford: Medicine Publishing Foundation, 1982: 305–9.
